Platelet Concentrate in Achilles Tendon Repair

Sponsor
University Hospital, Linkoeping (Other)
Overall Status
Completed
CT.gov ID
NCT00537784
Collaborator
(none)
30
1
2
22
1.4

Study Details

Study Description

Brief Summary

People operated for a rupture of the Achilles tendon receive a concentrate of their own platelets injected into the operated area. The study is randomized and single-blinded, with 20 treated patients and 20 controls, who get no injection. The primary endpoint is a mechanical property of the tendon after 12 weeks (modulus of elasticity), as measured by a special type of radiography. This radiography uses 0.8 mm metal markers, which are injected into the tendon. The tendon is mechanically loaded during radiography and its strain can be measured as increased distance between the markers. Other mechanical variables at 6, 12 and 52 weeks are secondary variables, as well as a validated patient-administrated questionaire at 1 year.

Condition or Disease Intervention/Treatment Phase
  • Biological: Autologous platelets
  • Biological: no injection
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Study Start Date :
Sep 1, 2007
Actual Primary Completion Date :
Jul 1, 2009
Actual Study Completion Date :
Jul 1, 2009

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: 1

Injection of autologous platelet concentrate into repair site

Biological: Autologous platelets
Local injection 10mL, about 2.5 x 10E10 platelets.

Placebo Comparator: 2

No injection

Biological: no injection

Outcome Measures

Primary Outcome Measures

  1. Modulus of elasticity [12 weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Achilles tendon rupture, age 18-65.
Exclusion Criteria:
  • Any counterindication for surgical treatment.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Univ Hosp Linköping Sweden Se 88185

Sponsors and Collaborators

  • University Hospital, Linkoeping

Investigators

  • Principal Investigator: per aspenberg, University of Linköping

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Per Aspenberg, professor, University Hospital, Linkoeping
ClinicalTrials.gov Identifier:
NCT00537784
Other Study ID Numbers:
  • Trombocytakilles
First Posted:
Oct 1, 2007
Last Update Posted:
Jun 19, 2013
Last Verified:
Jun 1, 2013
Keywords provided by Per Aspenberg, professor, University Hospital, Linkoeping
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 19, 2013